My wife had Lasik here. They’re always on time, the doctor has a great bedside manner, and she can now see clearly; even with our glasses! Highly recommend.
Christopher Foster
CMV Retinitis: What You Need to Know to Protect Your Vision
Who Is Most at Risk?
CMV retinitis does not affect people with healthy immune systems. It develops in those whose immune defenses have been significantly compromised, and certain groups face a much higher risk than others.
Historically, the most common group affected by CMV retinitis has been people with HIV, particularly those with advanced AIDS. The infection typically develops when CD4+ T-cell counts fall below 50 cells per microliter. It rarely occurs when counts remain above 100 cells per microliter.
People with HIV who are not receiving antiretroviral therapy, or whose treatment is no longer working effectively, are at the greatest risk. Very high HIV viral loads and a history of other opportunistic infections also increase the likelihood of developing CMV retinitis.
People who have received a solid organ transplant take immunosuppressive medications to prevent their body from rejecting the new organ. These medications lower the immune system's ability to fight infections, including CMV. The risk is greatest in patients who have never been exposed to CMV before but receive an organ from a donor who carries the virus.
Several other situations can weaken the immune system enough to allow CMV retinitis to develop. These include:
- Chemotherapy for cancer
- Long-term use of strong immunosuppressive medications for autoimmune diseases
- Congenital immune deficiencies present from birth
- Significant immune decline in elderly individuals
In some cases, strong local immunosuppression applied directly in or around the eye can be a risk factor, even without widespread immune suppression throughout the rest of the body.
Recognizing the Symptoms
One of the most challenging aspects of CMV retinitis is that it often causes no symptoms in its earliest stages. Knowing what to watch for is important for anyone with a weakened immune system, because early detection makes a meaningful difference in outcomes.
When symptoms do appear early on, the most common complaint is new floaters. Floaters are small spots, dots, or cobweb-like shapes that seem to drift across your field of vision. They occur because of changes taking place inside the eye as the infection develops.
Studies have found that roughly one in three patients with CMV retinitis had no symptoms at the time of diagnosis, which is why regular screening matters so much for high-risk individuals.
As CMV retinitis advances, symptoms become more noticeable. A shadow or dark area may appear in the side (peripheral) vision, and this shadow can gradually expand as more of the retina is affected. Blurred vision is also a common complaint as the disease progresses.
Some patients describe flashes of light or a veil-like effect across part of their visual field. If the infection reaches the macula, which is the central part of the retina responsible for sharp, detailed vision, significant central vision loss can occur. This type of vision loss is often permanent.
Certain vision changes require same-day or emergency attention. If you have a compromised immune system and notice any of the following, contact a retina specialist or go to an emergency room right away:
- A sudden increase in floaters
- Flashes of light in your vision
- A curtain, shadow, or dark veil moving across your field of vision
- Sudden vision loss in one eye
These symptoms may indicate rapidly advancing CMV retinitis or a retinal detachment, both of which require urgent evaluation. Do not wait to see if they improve on their own.
How CMV Retinitis Is Diagnosed
Diagnosing CMV retinitis begins with a careful, detailed examination of the back of the eye. Additional tests may be used to confirm the diagnosis or assess how much of the retina has been affected.
A dilated eye examination is the cornerstone of diagnosing CMV retinitis. During this exam, eye drops are used to widen the pupil so that the retina can be seen clearly. A retina specialist uses specialized lenses and instruments to examine the retina in detail.
The characteristic pattern of CMV retinitis, with its combination of pale, dead tissue and areas of hemorrhage, is often recognizable on examination. The location and extent of the infection are carefully documented so that treatment can be planned appropriately and progress can be tracked over time.
Because CMV retinitis so often causes no symptoms in its early stages, routine screening is essential for people who are at high risk. Patients with CD4+ T-cell counts below 50 cells per microliter should have follow-up eye examinations at least every three months, even when they feel no vision problems. Finding the infection early allows treatment to begin before significant vision loss occurs.
In some cases, further testing helps confirm the diagnosis or clarify the extent of the damage. Common additional tests include:
- Optical coherence tomography (OCT), which uses light waves to create detailed cross-sectional images of the retinal layers
- Fundus photography, which captures high-resolution photographs of the retina for monitoring changes over time
- Polymerase chain reaction (PCR) testing of a small sample of fluid from inside the eye, which can detect the presence of CMV DNA in uncertain cases
Your eye care team will determine which tests are appropriate based on your individual situation and the findings of your examination.
Treatment Approaches
Treatment for CMV retinitis is managed collaboratively between a retina specialist and your primary medical team. The goal is to stop the infection from spreading, preserve as much vision as possible, and address the underlying immune deficiency driving the condition.
The primary approach to treating CMV retinitis involves antiviral medications that work throughout the body. Several FDA-approved options are available, including ganciclovir, valganciclovir, foscarnet, and cidofovir. Oral valganciclovir is currently the most commonly used option because of its convenience and effective absorption.
Systemic treatment is preferred because CMV can affect other organs in addition to the eyes. Therapy usually begins with a higher induction dose for two to three weeks until the retinitis stabilizes, followed by a lower maintenance dose. Blood tests are performed regularly because some of these medications can affect blood cell counts or kidney function.
In some situations, antiviral medication is delivered directly into the eye through an intravitreal injection (an injection into the gel-filled space inside the eye). Medications such as ganciclovir and foscarnet can be administered this way to achieve fast, targeted control of the infection.
Intravitreal injections are often used alongside systemic therapy, especially when the infection is close to the macula or optic nerve and rapid treatment is needed. The decision to use intravitreal injections is based on the location and severity of the retinitis, as well as the patient's overall health and immune status.
For patients with HIV, restoring the immune system through highly active antiretroviral therapy (HAART) is the most important long-term strategy. The introduction of HAART has dramatically reduced both the number of new cases of CMV retinitis and the rate at which existing cases progress.
When CD4+ T-cell counts rise and remain at a healthy level, the risk of CMV reactivation drops significantly. Under close medical supervision, maintenance antiviral therapy may eventually be discontinued in patients who achieve sustained immune recovery. Ongoing eye examinations remain important even after therapy is stopped.
Living with CMV Retinitis
Managing CMV retinitis is an ongoing process that extends well beyond the initial treatment phase. Understanding what to expect and how to take an active role in your care can make a meaningful difference in preserving your quality of life and your remaining vision.
The single most important factor in preventing CMV retinitis from returning is maintaining the strongest possible immune system. For people with HIV, this means taking antiretroviral medications consistently and not missing doses. For transplant recipients, it means working closely with your transplant team to find the right balance between immunosuppression and infection risk.
Regular medical checkups and blood tests to monitor immune function are a critical part of ongoing care for anyone who has been affected by this condition.
Some patients experience lasting changes to their vision, particularly if the macula or optic nerve was involved before treatment began. Retinal tissue destroyed by CMV does not regenerate, and vision lost before treatment is typically not recoverable.
Low vision rehabilitation services can help patients make the most of their remaining vision. These services may include training with magnification devices, strategies for managing daily tasks, and adjustments to lighting and contrast in the home and workplace.
Facing a condition that threatens your vision, especially alongside an underlying immune disorder, can be emotionally difficult. Many patients find it helpful to connect with counseling services or support groups for people with visual impairment or immune conditions.
Your care team can help connect you with community and national organizations that offer resources for people living with HIV, organ transplants, or other immune-related conditions. You do not have to navigate this alone.
Frequently Asked Questions
The following questions address common concerns that patients and their families often raise about CMV retinitis, its management, and what to expect going forward.
Yes, reactivation is possible if the immune system weakens again, because the cytomegalovirus remains dormant in the body even after successful treatment. This is why maintenance antiviral therapy and ongoing monitoring are so important. If you are considering stopping maintenance therapy, this decision should always be made with your retina specialist and primary medical team based on your current immune status, not on the absence of symptoms alone.
The retinitis itself does not spread from person to person. However, the underlying cytomegalovirus is quite common and can be transmitted through bodily fluids such as saliva, blood, urine, and breast milk. Most people who are exposed to CMV do not develop retinitis, because a healthy immune system keeps the virus inactive. Only those with severely compromised immune systems are at risk for the retinitis complication, so standard hygiene practices are generally sufficient for those around you.
During the active induction phase of treatment, eye examinations are scheduled frequently, sometimes every week or two, to confirm that the borders of the infection are stabilizing. Once the condition is under control and you are on a maintenance regimen, the frequency of visits is adjusted based on your immune status and how stable your vision is. If your immune system is recovering well, visits may become less frequent over time, but they should never stop entirely without guidance from your eye care team.
Treatment can stop the virus from destroying additional retinal tissue, but it cannot restore the tissue that has already been lost. Vision that was reduced before treatment began typically does not return. For patients with lasting vision changes, low vision services and rehabilitation can help maximize the usability of remaining sight. This underscores how critical it is to seek evaluation promptly at the first sign of any vision changes, rather than waiting to see if they resolve.
For people with HIV, the most effective prevention is maintaining CD4+ T-cell counts well above 50 cells per microliter through consistent antiretroviral therapy. For transplant recipients, antiviral prophylaxis medications are sometimes prescribed during the period of greatest risk. For all high-risk patients, regular dilated eye examinations are an essential preventive tool, because the infection can be caught and treated before major vision loss occurs. If you have recently started or changed an immunosuppressive medication, let your eye doctor know so your screening schedule can be adjusted accordingly.
Schedule a Visit at NewView Eye Center
If you or someone you care for has a weakened immune system or has been diagnosed with CMV retinitis, our team at NewView Eye Center is here to help with thorough evaluation, expert co-management, and compassionate support. We are proud to serve patients across Northern Virginia with the personalized, excellence-driven eye care that every patient deserves. Contact us today to schedule an appointment at either of our convenient locations in Reston or Leesburg.
What our Patients Says
Explore More
Find more information about our doctors, services, and technology that keep your eyes healthy and your vision at its best.
Uveitis: Understanding Eye Inflammation and Protecting Your Vision
Retinal Disease: What Every Patient Needs to Know
Laser Floater Removal: Relief for Bothersome Eye Floaters
Vitreous Hemorrhage: Causes, Treatment, and Recovery
Vitrectomy Surgery: What Patients Need to Know
Retinopathy of Prematurity: A Guide for Parents